申请人:PathoGenesis Corporation
公开号:US05441955A1
公开(公告)日:1995-08-15
Methods, compounds and compositions are provided form inhibiting the growth of pathogenic mycobacteria in vitro and of treatment of pathogenic mycobacterial infections in vivo using indolo[2,1-b]quinazoline-6,12-dione compounds of the formula (I): ##STR1## wherein A, B, C, D, E, F, G and H are independently selected from carbon and nitrogen, or A and B or C and D can be taken together to be nitrogen or sulfur, and the pharmaceutically acceptable salts thereof. The methods, compounds and compositons are particularly useful for inhibiting the growth of Mycobacterium tuberculosis, and may be used alone, or in combination with other anti-Mycobacterium tuberculosis agents, such as isoniazid, rifampin, pyrazinamide, rifabutin, streptomycin and ciprofloxacin, to provide new agents for the treatment of tuberculosis, including multidrug-resistant tuberculosis (MDRTB).
提供了一种用于体外抑制病原性分枝杆菌生长和用于体内治疗病原性分枝杆菌感染的方法、化合物和组合物,使用式(I)的吲哚并[2,1-b]喹唑啉-6,12-二酮化合物:##STR1## 其中A、B、C、D、E、F、G和H独立地选自碳和氮,或A和B或C和D可以结合在一起成为氮或硫,并且其药学上可接受的盐。这些方法、化合物和组合物特别适用于抑制结核分枝杆菌的生长,并可单独使用,或与其他抗结核分枝杆菌药物(如异烟肼、利福平、吡嗪酰胺、利福布汀、链霉素和环丙沙星)结合使用,以提供用于治疗结核病的新药物,包括多药耐药结核病(MDRTB)。